Professor Shai Golan, MD

Urologic Oncologist

Position: Head of the Urology Department

Hospital: Rabin Medical Center (Beilinson, Hasharon, Schneider)

Chairman of the Urological Oncology Section of the Israeli Urology Association

Prof. Golan is in the Forbes list of the best doctors in Israel

Online Consultation. Second Opinion

Ask Doctor

Qualified Consultation of Urologic Oncologist Shai Golan :

• Urological Oncology
• Minimally Invasive and Robotic Urological Surgery
• Focal Treatments for Prostate Cancer (Cryotherapy, HIFU)
• Laparoscopic Surgery
• FUSION Prostate Biopsy
• Kidney Cancer: Laparoscopic and Robotic Nephrectomy
• Bladder Cancer: Endoscopic and Surgical Treatment
• Testicular Cancer: Diagnosis and Treatment
• Adrenal Tumors: Surgical Treatment
• Benign Prostatic Hyperplasia (BPH) and Diagnosis of Hematuria

Send Your Medical Files               Book an Appointment Now

Education and Training

• M.D. with Honors, Rappaport Faculty of Medicine, Technion – Israel Institute of Technology (2000-2007)
• Research Internship under the supervision of Nobel Prize Laureate Professor Aaron Ciechanover
• Urology Internship at the Mayo Clinic and the University of Minnesota Fairview Medical Center, USA (2005)
• Urology Residency, Rabin Medical Center (2007–2014)
• Research Fellowship, University of Chicago, USA (2011–2012)
• Clinical Fellowship in Minimally Invasive Urologic Oncology, University of Chicago, USA (2015–2017)
• Participant in hundreds of laparoscopic and robotic surgeries

Current Positions

• Head of the Urology Department, Rabin Medical Center (Beilinson, Hasharon, Schneider)
• Director of the Urologic Oncology Service, Rabin Medical Center
• Chairman of the Urologic Oncology Section, Israel Urological Association
• Senior Lecturer, Sackler Faculty of Medicine, Tel Aviv University
• Board Member Senior Lecturer, Tel Aviv University
• Examiner for National Urology Examinations

Academic and Teaching Activities

• Senior Lecturer, Sackler Faculty of Medicine, Tel Aviv University
• Director of the Urology Internship and Student Training Program, Rabin Medical Center
• Head of the Minimally Invasive Urological Surgery Course for Residents, Simulation Center, Sheba Medical Center (2010-2011)
• Developer and participant in the project to create a VR simulator for kidney and prostate surgeries

Professional Associations

• EuIsraeli Urological Association
• ropean Urological Association (EAU)
• American Urological Association (AUA)
• Society of Urological Oncology (SUO)

Professor Golan’s Research and Scientific Work

Professor Shai Golan is one of the leaders in the field of urological oncology in Israel. His medical discoveries directly impact the quality of treatment, increasing survival and reducing the risk of recurrence in patients with urological cancers.

• Founder of IUOC – Israel Urological Oncology Collaboration
• Active participation in clinical and basic research, presentations at international urological conferences
• Reviewer of leading international urological journals
• Winner of several awards from the Israeli Urological Association for outstanding scientific work (2010, 2014, 2019)

Some of his latest studies:

1. Improving survival in frail patients with bladder cancer (2024). A multicenter study that showed that individually tailored chemotherapy can significantly improve survival even in frail and severe patients who have undergone cystectomy.
2. The Burden and Consequences of Incomplete Treatment of Bladder Cancer (2024). Analysis of the natural history and health care costs associated with a palliative approach is important information for patients who are not candidates for aggressive treatment.
3. Prevention of Complications after Surgery for Prostate Cancer (2024, in press). Part of the PELYCAN clinical trial. The peritoneal flap has been shown to be effective in preventing lymphocele, a common complication after robot-assisted prostatectomy.
4. Breakthrough in Outpatient Bladder Cancer Treatment (2023). The study showed that a single administration of mitomycin C during the procedure (fulguration) significantly reduces the risk of recurrence in patients with superficial bladder cancer. 
5. A New Strategy for Aggressive Prostate Cancer (2023). The use of Lutetium-177-PSMA before surgery was studied in high-risk patients. The results show a dramatic decrease in PSA, opening up the prospect of a new approach to treatment.

Languages

• Hebrew
• English